Elevated plasma level of plasminogen activator inhibitor-1 (PAI-1) in patients with relapsing-remitting multiple sclerosis

Hiroshi Onodera, Ichiro Nakashima, Kazuo Fujihara, Tetsuya Nagata, Yasuto Itoyama

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)

Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system and one of the earliest changes in inflammatory focus involves the activation of vascular endothelial cells. We determined the plasma level of plasminogen activator inhibitor-1 (PAI-1), a key regulator of fibrinolysis and cell migration, in patients with MS. The level of plasma PAI-1 was significantly higher in active MS cases when compared to stable MS and controls. Plasma concentrations of tissue plasminogen activator, transforming growth factor β-1, and lipoprotein-a remained normal in spite of disease activity. These results suggested that PAI-1 plasma levels are associated with MS disease activity and is a good marker for MS relapse. - fibrinolysis; multiple sclerosis; plasminogen activator inhibitor-1; relapse

Original languageEnglish
Pages (from-to)259-265
Number of pages7
JournalTohoku Journal of Experimental Medicine
Volume189
Issue number4
DOIs
Publication statusPublished - 1999 Dec

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Elevated plasma level of plasminogen activator inhibitor-1 (PAI-1) in patients with relapsing-remitting multiple sclerosis'. Together they form a unique fingerprint.

Cite this